Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial von Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Chiu, Chao-Hua, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin, Chu, Quincy, Pujol, Jean-Louis, Moro-Sibilot, Denis, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Kim, Young Hak, Kurata, Takayasu, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Atagi, Shinji, Azuma, Koichi, Horio, Yoshitsugu, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Kaneda, Hiroyasu, Tomii, Keisuke, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Kim, Sang-We, Min, Young Joo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Lin, Meng-Chih, Su, Wu-Chou, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Acoba, Jared, Garon, Edward, Jung, Gabriel

Volltext

PD-1 Blockade in Anaplastic Thyroid Carcinoma von Capdevila, Jaume, Wirth, Lori J, Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O, Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A, Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M, Wrona, Anna, Santoro, Armando, Sadow, Peter M, Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

Volltext

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study von Gandara, David R., von Pawel, Joachim, Mazieres, Julien, Sullivan, Richard, Helland, Åslaug, Han, Ji-Youn, Ponce Aix, Santiago, Rittmeyer, Achim, Barlesi, Fabrice, Kubo, Toshio, Park, Keunchil, Goldschmidt, Jerome, Gandhi, Mayank, Yun, Cindy, Yu, Wei, Matheny, Christina, He, Pei, Sandler, Alan, Ballinger, Marcus, Fehrenbacher, Louis

Volltext

Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer von Blanc‐Durand, Félix, Camilleri, Geraldine M., Bayle, Arnaud, Aldea, Mihaela, Vasseur, Damien, Ouali, Kaissa, Michels, Judith, Pautier, Patricia, Nicotra, Claudio, Ngo‐Camus, Maud, Lacroix, Ludovic, Rouleau, Etienne, Ponce‐Aix, Santiago, Italiano, Antoine, Leary, Alexandra

Volltext

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer... von Morgensztern, Daniel, Cobo, Manuel, Ponce Aix, Santiago, Postmus, Pieter E., Lewanski, Conrad R., Bennouna, Jaafar, Fischer, Jürgen R., Juan‐Vidal, Oscar, Stewart, David J., Fasola, Gianpiero, Ardizzoni, Andrea, Bhore, Rafia, Wolfsteiner, Marianne, Talbot, Denis C., Jin Ong, Teng, Govindan, Ramaswamy, on behalf of the ABOUND.2L+ Investigators

Volltext

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial von Molina-Vila, Miguel-Angel, Stahel, Rolf A., Dafni, Urania, Jordana-Ariza, Núria, Balada-Bel, Ariadna, Garzón-Ibáñez, Mónica, García-Peláez, Beatriz, Mayo-de-las-Casas, Clara, Felip, Enriqueta, Curioni Fontecedro, Alessandra, Gautschi, Oliver, Peters, Solange, Massutí, Bartomeu, Palmero, Ramon, Ponce Aix, Santiago, Carcereny, Enric, Früh, Martin, Pless, Miklos, Popat, Sanjay, Cuffe, Sinead, Bidoli, Paolo, Kammler, Roswitha, Roschitzki-Voser, Heidi, Tsourti, Zoi, Karachaliou, Niki, Rosell, Rafael

Volltext

Chemotherapy for cholangiocarcinoma:An update von Natalia Ramírez-Merino Santiago Ponce Aix Hernán Cortés-Funes

Volltext

Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer von Aix Ponce, Santiago, Cousin, Sophie, Dubos, Paul, Belcaid, Laila, Bayle, Arnaud, Italiano, Antoine

Volltext

nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+) von Morgensztern, Daniel, Dols, Manuel Cobo, Ponce Aix, Santiago, Postmus, Pieter E, Bennouna, Jaafar, Fischer, Jürgen R, Juan-Vidal, Oscar, Stewart, David J, Ardizzoni, Andrea, Bhore, Rafia, Wolfsteiner, Marianne, Reck, Martin, Talbot, Denis, Govindan, Ramaswamy, Ong, Teng Jin

Volltext

High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial von Dziadziuszko, Rafal, Peled, Nir, Mok, Tony, Peters, Solange, Aix, Santiago Ponce, Alatorre-Alexander, Jorge, Vicuna, Brian D., Maclennan, Margaret, Bhagawati-Prasad, Vijay, Shagan, Sarah M., Schleifman, Erica, Ruf, Thorsten, Mathisen, Michael S., Gadgeel, Shirish M.

Volltext

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced... von Fehrenbacher, Louis, von Pawel, Joachim, Park, Keunchil, Rittmeyer, Achim, Gandara, David R., Ponce Aix, Santiago, Han, Ji-Youn, Gadgeel, Shirish M., Hida, Toyoaki, Cortinovis, Diego L., Cobo, Manuel, Kowalski, Dariusz M., De Marinis, Filippo, Gandhi, Mayank, Danner, Bradford, Matheny, Christina, Kowanetz, Marcin, He, Pei, Felizzi, Federico, Patel, Hina, Sandler, Alan, Ballinger, Marcus, Barlesi, Fabrice

Volltext

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) von Cedrés, Susana, Ponce-Aix, Santiago, Zugazagoitia, Jon, Sansano, Irene, Enguita, Ana, Navarro-Mendivil, Alejandro, Martinez-Marti, Alex, Martinez, Pablo, Felip, Enriqueta

Volltext

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC von Andric, Zoran, Gálffy, Gabriella, Cobo Dols, Manuel, Szima, Barna, Stojanovic, Goran, Petrovic, Marina, Felip, Enriqueta, Vicente Baz, David, Ponce Aix, Santiago, Juan-Vidal, Oscar, Szalai, Zsuzsanna, Losonczy, Gyorgy, Calles Blanco, Antonio, Bernabe, Reyes, García Ledo, Gema, Aguilar Hernández, Andrés, Duecker, Klaus, Zhou, Dongli, Schroeder, Andreas, Guezel, Guelseren, Ciardiello, Fortunato

Volltext

Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations von Rached, Layal, Laparra, Ariane, Sakkal, Madona, Danlos, François-Xavier, Barlesi, Fabrice, Carbonnel, Franck, De Martin, Eleonora, Ducreux, Michel, Even, Caroline, Le Pavec, Jerome, Michot, Jean-Marie, M. Ribeiro, Joana, Scotte, Florian, Ponce Aix, Santiago, Lambotte, Olivier, Baldini, Capucine, Champiat, Stéphane

Volltext

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer von Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T, Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A, Gandhi, Leena, Guba, Susan C, Diaz, Inmaculada Ales

Volltext

Antibody drug conjugates in older patients: State of the art von Rached, Layal, Geraud, Arthur, Frelaut, Maxime, AP Thomas, Zoe, Goldschmidt, Vincent, Beraud-Chaulet, Geoffroy, Nagera-Lazarovici, Celine, Danlos, Francois-Xavier, Henon, Clemence, Parisi, Claudia, Gazzah, Anas, Bahleda, Rastilav, Postel Vinay, Sophie, Smolenschi, Cristina, Hollebecque, Antoine, Michot, Jean-Marie, Ribrag, Vincent, Loriot, Yohann, Champiat, Stephane, Ouali, Kaissa, Massard, Christophe, Ponce Aix, Santiago, Bringuier, Michael, Baldini, Capucine

Volltext

Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study von Tan, Daniel S.W., Kim, Sang-We, Ponce Aix, Santiago, Sequist, Lecia V., Smit, Egbert F., Yang, James C.H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohé, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica, Kim, Dong-Wan

Volltext

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma von Ferrer, Irene, Quintanal-Villalonga, Álvaro, Molina-Pinelo, Sonia, Garcia-Heredia, Jose Manuel, Perez, Marco, Suárez, Rocío, Ponce-Aix, Santiago, Paz-Ares, Luis, Carnero, Amancio

Volltext

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels von Ramos-Paradas, Javier, Hernández-Prieto, Susana, Lora, David, Sanchez, Elena, Rosado, Aranzazu, Caniego-Casas, Tamara, Carrizo, Nuria, Enguita, Ana Belén, Muñoz-Jimenez, María Teresa, Rodriguez, Borja, Perez-Gonzalez, Urbicio, Gómez-Sánchez, David, Ferrer, Irene, Ponce Aix, Santiago, Nuñez Buiza, Ángel, Garrido, Pilar, Palacios, José, Lopez-Rios, Fernando, Garrido-Martin, Eva M, Paz-Ares, Luis

Volltext

Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis von Arriola, Edurne, Trigo, José Manuel, Sánchez-Gastaldo, Amparo, Navarro, Alejandro, Perez, Coral, Crama, Leonardo, Ponce-Aix, Santiago

Volltext